Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

Roche has learned a lot about gantenerumab during more than a decade of research and development, and it has used those lessons to execute a second set of Phase III clinical trials that could position the monoclonal antibody as a leading disease-modifying Alzheimer’s treatment – even though it may not be the first anti-amyloid therapy on the market – if the amyloid hypothesis holds up in its ongoing trials. 

No company has delivered a clearly successful set of Phase III results for an amyloid-targeting antibody, though Biogen presented a complex dataset on 5 December at the Clinical Trials on Alzheimer’s Disease (CTAD) meeting in San Diego that showed a subset of patients treated with the highest dose of aducanumab for the longest amount of time benefitted in the EMERGE and ENGAGE studies